Cargando…

Reply to: ‘Interaction between RAAS inhibitors and ACE2 in the context of COVID-19’

Detalles Bibliográficos
Autores principales:	Zheng, Ying-Ying, Ma, Yi-Tong, Zhang, Jin-Ying, Xie, Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104711/ https://www.ncbi.nlm.nih.gov/pubmed/32231330 http://dx.doi.org/10.1038/s41569-020-0369-9

Ejemplares similares

Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Reply to: RAAS inhibitors in COVID-19: not all are created equal!
por: Gonçalves, Jorge, et al.
Publicado: (2023)

RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)

RAAS, ACE2 and COVID-19; a mechanistic review
por: Elshafei, Ahmed, et al.
Publicado: (2021)

SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors
por: Milne, Stephen, et al.
Publicado: (2020)

Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021)

Antifibrotic Roles of RAAS Blockers: Update
por: Zhang, Ying-Ying, et al.
Publicado: (2019)

The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
por: Zhang, Jishou, et al.
Publicado: (2020)

RAAS INHIBITORS ARE CARDIOPROTECTIVE IN PATIENTS WITH COVID-19
por: Holmes, Adam R., et al.
Publicado: (2021)

ACE2, SARS-CoV-2 und RAAS-Blocker
por: Kintscher, Ulrich, et al.
Publicado: (2021)

Models for mortality require tailoring in the context of the COVID-19 pandemic – Authors' reply
por: Banerjee, Amitava, et al.
Publicado: (2020)

RAAS inhibitors do not increase the risk of COVID-19
por: Fernández-Ruiz, Irene
Publicado: (2020)

COVID-19 and RAAS inhibitors: is there a final conclusion?
por: Talebi-Taher, Mahshid, et al.
Publicado: (2021)

RAAS inhibitors in COVID-19: not all are created equal!
por: Kow, Chia Siang, et al.
Publicado: (2023)

Reply to “Protective effects of eosinophils against COVID-19: More than an ACE(2) in the hole?”
por: Ferastraoaru, Denisa, et al.
Publicado: (2021)

Reply
por: Yang, Xu, et al.
Publicado: (2016)

Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality
Publicado: (2020)

Reply to: Neuroimmune interactions and COVID-19 in lung transplant recipients
por: De Virgiliis, Francesco, et al.
Publicado: (2021)

Ceftazidime exhibits a broad inhibition to the infection of SARS-CoV-2 prototype and Omicron variant in vitro by blocking spike protein-ACE2 interaction
por: Zheng, Yun-zhe, et al.
Publicado: (2023)

Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein–ACE2 interaction
por: Yuan, MengYa, et al.
Publicado: (2021)

Reply to Polverino: Cigarette Smoking and COVID-19: A Complex Interaction
por: Cai, Guoshuai, et al.
Publicado: (2020)

Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Beechinor, R., et al.
Publicado: (2022)

Authors’ reply to ‘Multiple comparisons controversies are about context and costs, not frequentism versus Bayesianism’
por: Sjölander, Arvid, et al.
Publicado: (2019)

ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System
por: Michaud, Veronique, et al.
Publicado: (2020)

Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2022)

ACE2 Elevation in Severe COVID-19
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2021)

Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
por: Wang, James Jiqi, et al.
Publicado: (2020)

A Shot in the Dark! RAAS Inhibitors Cause Severe COVID-19 Infection
por: Krishna, Bhuvana
Publicado: (2021)

Reply to: COVID-19 and Coagulopathy
por: Rodríguez, Cristina, et al.
Publicado: (2021)

Reply to Lipworth et al.: Sex Hormones and Asthma: Don’t Forget Progesterone
por: Han, Yueh-Ying, et al.
Publicado: (2020)

Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors
por: Kloner, Robert A., et al.
Publicado: (2018)

Manipulation of ACE2 expression in COVID-19
por: Chaudhry, Farhan, et al.
Publicado: (2020)

Reply to "Does MAFLD really increase the severity of COVID-19?"
por: Pan, Lu, et al.
Publicado: (2021)

Authors’ Reply: A comparison of different methods to handle missing data in the context of propensity score analysis
por: Choi, Jungyeon, et al.
Publicado: (2019)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) I: Endogenous Angiotensin Converting Enzyme (ACE) Inhibition
por: Fagyas, Miklós, et al.
Publicado: (2014)

Cancer and COVID-19 – Authors' reply
por: Kuderer, Nicole M, et al.
Publicado: (2020)

Remdesivir and COVID-19 – Authors' reply
por: Wang, Yeming, et al.
Publicado: (2020)

Long COVID in children – Authors' reply
por: Molteni, Erika, et al.
Publicado: (2022)

Reply to: Hypertension and severe COVID-19
por: Shibata, Shigeru, et al.
Publicado: (2023)

Reply to Chen et al.
por: Chen, Zhanghua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rdb9fc24d98172i40ap57naulp